Get the Stockscreener App
1.75
4.17%
0.07
Pre-market:
1.75
Gain Therapeutics Inc stock is traded at $1.75, with a volume of 447.09K.
It is up +4.17% in the last 24 hours and up +0.00% over the past month.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
See More
Previous Close:
$1.68
Open:
$1.71
24h Volume:
447.09K
Relative Volume:
0.69
Market Cap:
$74.64M
Revenue:
$55,200
Net Income/Loss:
$-21.24M
P/E Ratio:
-2.9737
EPS:
-0.5885
Net Cash Flow:
$-19.37M
1W Performance:
+3.55%
1M Performance:
+0.00%
6M Performance:
-55.70%
1Y Performance:
+1.16%
1-Day Range:
$1.70
$1.79
1-Week Range:
$1.56
$1.79
52-Week Range:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.75 | 74.64M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
GANX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - The Manila Times
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - GlobeNewswire Inc.
Bial Ends Development Of Parkinson’s Disease Drug After Phase IIb Fail - Citeline News & Insights
Niemann-Pick Type Pipeline Gains Momentum: 10+ Companies Lead - openPR.com
Which stocks are moving after the closing bell on Monday? - ChartMill
Dyne Therapeutics (DYN) investors double share authorization and approve all proposals - Stock Titan
TVTX: FILSPARI cements its role in rare kidney disease, with robust growth and pipeline innovation - TradingView
Tango Therapeutics Shares Surge 32% on Strong Clinical Momentum in Precision Oncology - International Business Times Australia
Monday's pre-market session: top gainers and losers - ChartMill
GAIN THERAPEUTICS INC (GANX) Stock Chart - ChartMill
OPKO Health (OPK) Amends Partnership With Nicoya Therapeutics to Gain Equity Stake - Insider Monkey
Gain Therapeutics (GANX) price target increased by 11.76% to 7.75 - MSN
4 Biotech Stocks Investors Should Watch in 2026 - TradingView
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s? - TradingView
Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic... - markets.businessinsider.com
Wondering what's happening in today's pre-market session? - ChartMill
GANX Q1 2026 Earnings: Positive EPS Surprise Amidst Pre-Revenue StageHealthcare Earnings Report - newsline.com
Protagonist Therapeutics Jumps 6.1% Amid Sector-Wide Rally - AlphaStreet
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy - Yahoo Finance
Halozyme Therapeutics Jumps 5.4% Amid Sector-Wide Rally - AlphaStreet
Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday - Benzinga
TG Therapeutics Surges 10.2% Amid Sector-Wide Rally - AlphaStreet
Gain Therapeutics Inc. (GANX) Declines 1.64% as Stock Hovers Near Key Support LevelQuote Data - newsline.com
CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Prostate cancer study in The Lancet Oncology finds 30% DFS boost - Stock Titan
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Travere Therapeutics (TVTX) - The Globe and Mail
GANX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Double-Digit Share RallyNegative Surprise Momentum - The Legal Advocate
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Gain Therapeutics (GANX) Surges 14.7% as Volume Picks Up, Testing Resistance at $2.13Buy Signal Reports - The Legal Advocate
Trevi Therapeutics (TRVI) Holds Near Resistance After Modest GainBuffered ETF - The Legal Advocate
Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Gain Therapeutics stock maintained at Outperform by Oppenheimer - Investing.com
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate - Yahoo Finance
Gain Therapeutics (GANX) Climbs Higher as Bullish Momentum Builds Near ResistanceBollinger Walk - The Legal Advocate
Gain Therapeutics Releases First Quarter 2026 Financial Results and Corporate Update - geneonline.com
Gain Therapeutics Announces Interim Clinical and Biomarker Data from Phase 1B Study of GT-02287 in Parkinson's Disease - marketscreener.com
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate - TipRanks
GT-02287 shows biomarker, symptom stability in Gain (GANX) Parkinson’s study - Stock Titan
Gain Therapeutics says MDS-UPDRS scores remain stable after 150 days of GT-2287 treatment - marketscreener.com
Gain Therapeutics presents phase 1b data on Parkinson’s drug By Investing.com - Investing.com Australia
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 - The Manila Times
Gain Therapeutics presents phase 1b data on Parkinson’s drug - Investing.com
Parkinson’s patients report better smell, sleep, balance on experimental GT-02287 - Stock Titan
Gain Therapeutics Inc. Q1 2026 Earnings: EPS Surprise Highlights Cost Discipline Amid Pre-Revenue StageShare Dilution Risk - newsline.com
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s - Yahoo Finance
Gain Therapeutics (GANX) Bounces Back: Testing Key Resistance at $1.87Overvalued Signals - Newser
Gain Therapeutics Inc. (GANX) Q1 2026 Earnings: Narrower Loss Surpasses Estimates, Stock Edges HigherSaaS Earnings Trends - Newser
Gain Therapeutics (GANX) Edges Higher as Biotech Sector Shows Mixed SignalsTrading Community Hub - Newser
Gain Therapeutics (GANX) Edges Higher as Shares Approach Key Resistance LevelPCR Extreme - newsline.com
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):